- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02070120
Onderzoek naar blaaschemotherapie in plaats van chirurgie voor blaaskanker met een laag risico (CALIBER)
CALIBER - Een gerandomiseerde fase II-haalbaarheidsstudie van chemosectie en chirurgische behandeling bij niet-spierinvasieve blaaskanker met een laag risico
Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic. This multicentre study aims to establish the short term efficacy of chemoresection using chemotherapy within the bladder for the treatment of NMIBC.
Should the levels of complete response following chemoresection meet predefined criteria, a larger phase III trial would be developed to assess longer term disease related endpoints, with the aim of standardising management of recurrent low risk NMIBC and potentially removing the need for over a thousand patients each year to undergo surgery.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
CALIBER is a two stage phase II, multicentre, randomised controlled trial (RCT). A control group has been included to provide prospective data about surgical management and outcomes and assess feasibility of recruitment to a randomised study.
Stage 1: 80 patients will be recruited with treatment allocated 2:1 by randomisation between chemoresection and surgical management.
Stage 2: If the stop/go activity criteria at the end of stage 1 indicate that recruitment should continue, 9 additional participants will be recruited, all of whom will receive chemoresection.
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg Mitomycin C (MMC) as outpatients. This treatment will be delivered via catheter under local anaesthetic.
Patients assigned to the surgical management group will receive the standard surgical management in use at their hospital for treatment of recurrence which may include a single post-operative installation of 40mg MMC within 24 hours.
All participants will be followed up at 3 weeks from the start of treatment (ie at time of final MMC instillation for chemoresection group) and each will receive a cystoscopy three months from the end of treatment to assess response, in accordance with European Association of Urology (EAU) guidelines.
Subsequent cystoscopic follow up will take place 12 months after treatment if recurrence-free at 3 months and then annually.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
London, Verenigd Koninkrijk, NW1 2BU
- University College Hospital
-
Manchester, Verenigd Koninkrijk, M23 9LT
- Wythenshawe Hospital
-
Manchester, Verenigd Koninkrijk, M20 2LR
- Withington Hospital
-
-
Cheshire
-
Macclesfield, Cheshire, Verenigd Koninkrijk, SK10 3BL
- Macclesfield District General Hospital
-
-
Cleveland
-
Middlesbrough, Cleveland, Verenigd Koninkrijk, TS4 3BW
- James Cook University Hospital
-
-
Cumbria
-
Whitehaven, Cumbria, Verenigd Koninkrijk, CA28 8JG
- West Cumberland Hospital
-
-
Devon
-
Exeter, Devon, Verenigd Koninkrijk, EX2 5DW
- Royal Devon and Exeter Hospital
-
Plymouth, Devon, Verenigd Koninkrijk, PL6 8DH
- Derriford Hospital
-
-
Dorset
-
Bournemouth, Dorset, Verenigd Koninkrijk, BH7 7DW
- Royal Bournemouth Hospital
-
Dorchester, Dorset, Verenigd Koninkrijk, DT1 2JY
- Dorset County Hospital
-
-
England
-
Carlisle, England, Verenigd Koninkrijk, CA2 7HY
- Cumberland Infirmary
-
-
Essex
-
Chelmsford, Essex, Verenigd Koninkrijk, CM1 5ET
- Broomfield Hospital
-
Harlow, Essex, Verenigd Koninkrijk, CM20 1QX
- Princess Alexandra Hospital
-
-
Gloucestershire
-
Cheltenham, Gloucestershire, Verenigd Koninkrijk, GL53 7AN
- Cheltenham General Hospital
-
Gloucester, Gloucestershire, Verenigd Koninkrijk, GL1 3NN
- Gloucestershire Royal Hospital
-
-
Greater Manchester
-
Manchester, Greater Manchester, Verenigd Koninkrijk, OL1 2JH
- Royal Oldham Hospital
-
-
Hampshire
-
Basingstoke, Hampshire, Verenigd Koninkrijk, RG24 9NA
- Basingstoke and North Hampshire Hospital
-
Southampton, Hampshire, Verenigd Koninkrijk, SO16 6YD
- Southampton General Hospital
-
-
Herefordshire
-
Hereford, Herefordshire, Verenigd Koninkrijk, HR1 2ER
- Hereford County Hospital
-
-
Kent
-
Dartford, Kent, Verenigd Koninkrijk, DA2 8DA
- Darent Valley Hospital
-
Gillingham, Kent, Verenigd Koninkrijk, ME7 5NY
- Medway Maritime Hospital
-
-
Lancashire
-
Preston, Lancashire, Verenigd Koninkrijk, PR2 9HT
- Royal Preston Hospital
-
-
Leicestershire
-
Leicester, Leicestershire, Verenigd Koninkrijk, LE5 4PW
- Leicester General Hospital
-
-
Middlesex
-
Harrow, Middlesex, Verenigd Koninkrijk, HA1 3UJ
- Northwick Park Hospital
-
-
Oxfordshire
-
Headington, Oxfordshire, Verenigd Koninkrijk, OX3 7LE
- Churchill Hospital
-
-
South Yorkshire
-
Sheffield, South Yorkshire, Verenigd Koninkrijk, S10 2JF
- Royal Hallamshire Hospital
-
-
Suffolk
-
Ipswich, Suffolk, Verenigd Koninkrijk, IP4 5PD
- Ipswich Hospital
-
-
Surrey
-
Croydon, Surrey, Verenigd Koninkrijk, CR7 7YE
- Croydon University Hospital
-
Guildford, Surrey, Verenigd Koninkrijk, GU2 7XX
- Royal Surrey County Hospital
-
-
Tyne and Wear
-
Newcastle upon Tyne, Tyne and Wear, Verenigd Koninkrijk, NE7 7DN
- Freeman Hospital
-
-
West Midlands
-
Wolverhampton, West Midlands, Verenigd Koninkrijk, WV10 0QP
- New Cross Hospital
-
-
West Sussex
-
Chichester, West Sussex, Verenigd Koninkrijk, PO19 6SE
- St Richard's Hospital
-
Worthing, West Sussex, Verenigd Koninkrijk, BN11 2DH
- Worthing Hospital
-
-
West Yorkshire
-
Wakefield, West Yorkshire, Verenigd Koninkrijk, WF1 4DG
- Pinderfields General Hospital
-
-
Worcestershire
-
Kidderminster, Worcestershire, Verenigd Koninkrijk, DY11 6RJ
- Kidderminster Hospital
-
Redditch, Worcestershire, Verenigd Koninkrijk, B98 7UB
- Alexandra Hospital
-
Worcester, Worcestershire, Verenigd Koninkrijk, WR5 1DD
- Worcester Royal Hospital
-
-
Yorkshire
-
Leeds, Yorkshire, Verenigd Koninkrijk, LS9 7TF
- St James's University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Written informed consent
- NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables
- Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis
- Aged 16 or over
- Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit of Normal (ULN)
- Negative pregnancy test for women of child-bearing potential
Exclusion Criteria:
- Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
- Any history of histologically confirmed non-TCC bladder cancer
- Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
- Any prior treatment of the trial entry recurrence (including biopsy)
- Previous MMC chemotherapy other than a single instillation at diagnostic surgery
- Known allergy to MMC
- Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
- Known or suspected reduced bladder capacity (<100ml)
- Significant bleeding disorder
- Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active.
- Active or intractable urinary tract infection
- Urethral stricture or anything impeding the insertion of a catheter
- Large narrow neck diverticula
- Significant urinary incontinence
- Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
- Unable or unwilling to comply with study procedures or follow up schedule
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Chemoresection
4 once weekly outpatient intravesical instillations 40mg Mitomycin C |
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
Andere namen:
|
|
Ander: Surgical Management
Surgical management according to local practice |
Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Complete response rate with chemoresection
Tijdsspanne: 3 months
|
Defined as an absence of any tumour following chemoresection and will be assessed visually at 3 month check cystoscopy by patients' urologists. A biopsy of the tumour bed would take place to confirm visual assessment of complete response. |
3 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Treatment compliance in chemoresection group
Tijdsspanne: Duration of treatment (3 weeks)
|
Patients who receive 4 MMC instillations with no more than 14 days between each instillation will be described as fully compliant. |
Duration of treatment (3 weeks)
|
|
Salvage surgery rates
Tijdsspanne: 3 years
|
Assessing trans-urethral resection and biopsy rates following initial treatment in both treatment groups |
3 years
|
|
Progression-free survival
Tijdsspanne: 3 years
|
Defined as time from randomisation to the first of muscle invasive bladder recurrence, recurrence in the pelvic nodes, distant metastatic recurrence or death from any cause. |
3 years
|
|
Toxicity (NCI Common Toxicity Criteria for Adverse Effects (CTCAE) V4 and Clavien Dindo grade (in surgical group))
Tijdsspanne: up to 12 months
|
Measuring side effects of both treatments using clinician reported toxicity scales |
up to 12 months
|
|
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and Superficial Bladder Cancer (BLS24) questionnaire
Tijdsspanne: up to 12 months
|
Assessing side effects and impact of both treatments on patient reported quality of life. |
up to 12 months
|
|
Health service utilisation
Tijdsspanne: up to 12 months
|
Assessed using prospective data collection of health resource usage. |
up to 12 months
|
|
Recurrence free interval
Tijdsspanne: up to 12 months
|
Time from end of treatment to first relapse, in patients confirmed recurrence free at 3 months |
up to 12 months
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Hugh Mostafid, Royal Surrey County Hospital NHS Foundation Trust
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Mannelijke urogenitale ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Urologische neoplasmata
- Ziekten van de urineblaas
- Neoplasmata van de urineblaas
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Indolen
- Chinones
- Azirines
- Mitomycines
- Indolequinonen
- Mitomycine
Andere studie-ID-nummers
- ICR-CTSU/2013/10041
- 2013-005095-18 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .